Literature DB >> 33377648

Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling.

Szu-Yuan Wu1,2,3,4,5, Wan-Yu Yang6, Chun-Chia Cheng6,7, Kuan-Hao Lin6, Bonifasius Putera Sampurna6, Suat-Ming Chan6, Chiou-Hwa Yuh6,8,9,10.   

Abstract

BACKGROUND: Hepatocellular carcinoma ranks fourth in cancer-related mortality currently lacks effective therapeutics. Fucoidan is sulfated polysaccharide that is mainly found in brown seaweeds. In this study, we investigated the effects and mechanisms of low molecular weight fucoidan (i.e. oligo-fucoidan [OF]) preventing hepatocarcinogenesis.
METHODS: We used [HBx,src], [HBx,src,p53-/+ ], and [CD36] transgenic zebrafish liver cancer model treated with OF, and performed molecular and histopathological analysis. Transcriptomic and pathways analysis was performed.
RESULTS: Decreased expression of lipogenic enzymes, fibrosis markers, and cell cycle/proliferation markers by OF in [HBx,src] and [HBx,src,p53-/+ ] transgenic fish. Liver fibrosis was decreased as revealed by Sirius Red staining, and the liver cancer formation was eventually reduced by feeding OF. OF was also found to be capable of reducing lipid accumulation and cancer formation in non-B non-C Hepatocellular carcinoma (HCC) model in CD36 transgenic zebrafish. Whole-genome expression analysis showed that 661 genes were up-regulated, and 451 genes were downregulated by feeding OF. Upregulated genes were mostly found in protein transporter activity, and downregulated genes were enriched with response to extracellular stimulus and metal binding in gene ontology analysis. The driver gene was HNF4A revealed by NetworkAnalyst from OF differential regulated genes at various insults. OF is able to bind the asialoglycoprotein receptor (ASGR) in hepatoma cells, and increased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) in both hepatoma cells and [HBx,src,p53-/+ ] transgenic fish liver cancer model. Using chromatin-immunoprecipitation, we found pSTAT3 could associate with the P1 promoter of HNF4A. Knockdown of either ASGR or HNF4A reversed OF mediated anti-cancer cell proliferation.
CONCLUSIONS: Taken together, we provide evidence that OF exhibits the anti-HCC, anti-steatosis, and anti-fibrosis effect for liver in zebrafish models, and the anti-cancer potential of OF attributed to the binding to ASGR and activation of STAT3/HNF4A signaling. OF might be potentially valuable for the management of HCC.
© 2020 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  hepatocellular carcinoma; oligo-fucoidan; therapeutics; zebrafish

Year:  2017        PMID: 33377648      PMCID: PMC7752165          DOI: 10.1002/ctm2.252

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


  65 in total

1.  An evolutionarily conserved kernel of gata5, gata6, otx2 and prdm1a operates in the formation of endoderm in zebrafish.

Authors:  Wen-Fang Tseng; Te-Hsuan Jang; Chang-Ben Huang; Chiou-Hwa Yuh
Journal:  Dev Biol       Date:  2011-07-01       Impact factor: 3.582

2.  Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides.

Authors:  Elena Riboldi; Roberta Daniele; Carmen Parola; Antonio Inforzato; Phoebe L Arnold; Daniela Bosisio; Daved H Fremont; Antonio Bastone; Marco Colonna; Silvano Sozzani
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

Review 3.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

4.  The structure property and endothelial protective activity of fucoidan from Laminaria japonica.

Authors:  Anjin Chen; Ying Lan; Jingwen Liu; Fang Zhang; Lijuan Zhang; Bafang Li; Xue Zhao
Journal:  Int J Biol Macromol       Date:  2017-07-25       Impact factor: 6.953

5.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

Authors:  M H Chang; C J Chen; M S Lai; H M Hsu; T C Wu; M S Kong; D C Liang; W Y Shau; D S Chen
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

Review 6.  Fucoidan and cancer: a multifunctional molecule with anti-tumor potential.

Authors:  Farzaneh Atashrazm; Ray M Lowenthal; Gregory M Woods; Adele F Holloway; Joanne L Dickinson
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

7.  Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in a Zebrafish Model.

Authors:  Szu-Yuan Wu; Wan-Yu Yang; Chun-Chia Cheng; Ming-Chen Hsiao; Shin-Lin Tsai; Hua-Kuo Lin; Kuan-Hao Lin; Chiou-Hwa Yuh
Journal:  Cancers (Basel)       Date:  2020-06-18       Impact factor: 6.639

8.  Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile.

Authors:  Kai-Wen Huang; Vikash Reebye; Katherine Czysz; Simona Ciriello; Stephanie Dorman; Isabella Reccia; Hong-Shiee Lai; Ling Peng; Nikos Kostomitsopoulos; Joanna Nicholls; Robert S Habib; Donald A Tomalia; Pål Sætrom; Edmund Wilkes; Pedro Cutillas; John J Rossi; Nagy A Habib
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-21       Impact factor: 8.886

9.  Fucoidan inhibits the growth of hepatocellular carcinoma independent of angiogenesis.

Authors:  Cong Zhu; Rui Cao; Shuang-Xia Zhang; Ya-Nan Man; Xiong-Zhi Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-12       Impact factor: 2.629

Review 10.  Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.

Authors:  Joanne Marie O'Rourke; Vandana Mridhu Sagar; Tahir Shah; Shishir Shetty
Journal:  World J Gastroenterol       Date:  2018-10-21       Impact factor: 5.742

View more
  2 in total

Review 1.  The role of hepatocyte nuclear factor 4α (HNF4α) in tumorigenesis.

Authors:  Lei Sang; Xingshun Wang; Weiyu Bai; Junling Shen; Yong Zeng; Jianwei Sun
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

Review 2.  The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles.

Authors:  Jun-O Jin; Pallavi Singh Chauhan; Ananta Prasad Arukha; Vishal Chavda; Anuj Dubey; Dhananjay Yadav
Journal:  Mar Drugs       Date:  2021-05-10       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.